You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

LDX

Showing 1 - 25 of 107
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Binge-Eating Disorder, Obesity Trial in New Haven (drug, behavioral, other)

Recruiting
  • Binge-Eating Disorder
  • Obesity
  • Lisdexamfetamine Dimesylate
  • +2 more
  • New Haven, Connecticut
    Yale Department of Psychiatry
Jan 6, 2022

ADHD Trial in New York (Guanfacine, Lisdexamfetamine)

Terminated
Has Results
  • Attention Deficit Hyperactivity Disorder
  • New York, New York
    New York State Psychiatric Institute
Jan 18, 2023

Binge-Eating Disorder, Obesity Trial in New Haven (Lisdexamfetamine Dimesylate, Placebo)

Recruiting
  • Binge-Eating Disorder
  • Obesity
  • Lisdexamfetamine Dimesylate
  • Placebo
  • New Haven, Connecticut
    Yale Department of Psychiatry
Jan 6, 2022

Binge-Eating Disorder, Obesity Trial in New Haven (Naltrexone and Bupropion, Placebo)

Recruiting
  • Binge-Eating Disorder
  • Obesity
  • Naltrexone and Bupropion
  • Placebo
  • New Haven, Connecticut
    Yale Department of Psychiatry
Dec 21, 2022

Methamphetamine Abuse, Methamphetamine-dependence, Addiction, Substance Trial in Canada (Treatment as Usual plus Placebo,

Not yet recruiting
  • Methamphetamine Abuse
  • +3 more
  • Treatment as Usual plus Placebo
  • +3 more
  • Vancouver, British Columbia, Canada
  • +3 more
May 2, 2023

Healthy Trial in Miami (LDX + Venlafaxine XR, Venlafaxine XR + LDX)

Completed
Has Results
  • Healthy
  • LDX + Venlafaxine XR
  • Venlafaxine XR + LDX
  • Miami, Florida
    Clinical Pharmacology of Miami
Jun 8, 2021

Attention Deficit Disorder With Hyperactivity, Diabetes, Type 1 Trial (parental training in behavior management,

Not yet recruiting
  • Attention Deficit Disorder With Hyperactivity
  • Diabetes Mellitus, Type 1
  • parental training in behavior management
  • +2 more
  • (no location specified)
Jul 19, 2023

Type 1 Diabetes Trial in Pittsburgh, Frosinone, Rome (Ladarixin, Placebo)

Recruiting
  • Type 1 Diabetes
  • Pittsburgh, Pennsylvania
  • +2 more
Nov 21, 2022

Attention-Deficit Hyperactivity Disorder Trial in Houston (Lisdexamfetamine Dimesylate (LDX), Immediate Release Mixed

Completed
Has Results
  • Attention-Deficit Hyperactivity Disorder
  • Lisdexamfetamine Dimesylate (LDX)
  • +2 more
  • Houston, Texas
    Claghorn-Lesem Research Clinic
Jun 8, 2021

Schizophrenia Trial in Irving (SPD489 40mg, SPD489 100mg, SPD489 160mg)

Terminated
Has Results
  • Schizophrenia
  • SPD489 40mg
  • +3 more
  • Irving, Texas
    University Hills Clinical Research
May 29, 2021

Type I Diabetes Trial in Pittsburgh (Ladarixin, Placebo)

Withdrawn
  • Type I Diabetes
  • Pittsburgh, Pennsylvania
    Institute of Cellular Therapeutics Allegheny Health Network
Jan 17, 2022

no Condition Trial in Arzo (Ladarixin)

Completed
Has Results
  • no Condition
  • Arzo, Canton Ticino, Switzerland
    CROSS Research S.A., I Unit
Jan 10, 2022

Negative Symptoms of Schizophrenia Trial (SPD489 Low-Dose, SPD489 High-Dose, Placebo)

Withdrawn
  • Negative Symptoms of Schizophrenia
  • SPD489 Low-Dose
  • +2 more
  • (no location specified)
Jun 1, 2021

ADHD Trial in Ghent (LDX., sugar pill, computer task (Go/No-Go task))

Withdrawn
  • Attention Deficit Hyperactivity Disorder
  • Ghent, Belgium
  • +1 more
Nov 19, 2021

ADHD (ADHD) Trial in United States (LDX 30 mg, LDX 50 mg, LDX 70 mg)

Completed
Has Results
  • Attention Deficit Hyperactivity Disorder (ADHD)
  • LDX 30 mg
  • +3 more
  • Little Rock, Arkansas
  • +44 more
Jun 8, 2021

Schizophrenia Trial in United States (SPD489 low dose range (40mg, 80mg, and 100mg), SPD489 high dose range (120mg, 140mg and

Terminated
Has Results
  • Schizophrenia
  • SPD489 low dose range (40mg, 80mg, and 100mg)
  • +2 more
  • Miami Springs, Florida
  • +3 more
May 29, 2021

Healthy Trial in Hackensack (SPD503, VYVANSE, SPD503 and VYVANSE)

Completed
Has Results
  • Healthy
  • Hackensack, New Jersey
    Advanced Biomedical Research, Inc.
Jun 10, 2021

Bulimia Nervosa Trial in Halifax (Lisdexamfetamine dimesylate)

Terminated
  • Bulimia Nervosa
  • Lisdexamfetamine dimesylate
  • Halifax, Nova Scotia, Canada
    Nova Scotia Health Authority
Nov 25, 2020

Schizophrenia Trial in Glendale, Long Beach (SPD489 (Lisdexamfetamine dimesylate), Placebo)

Completed
Has Results
  • Schizophrenia
  • SPD489 (Lisdexamfetamine dimesylate)
  • Placebo
  • Glendale, California
  • +1 more
May 13, 2021

Binge Eating, Eating Behavior Trial in Birmingham (Placebo oral tablet, Lisdexamfetamine Dimesylate)

Terminated
  • Binge Eating
  • Eating Behavior
  • Placebo oral tablet
  • Lisdexamfetamine Dimesylate
  • Birmingham, United Kingdom
    University of Birmingham
Nov 4, 2020

Schizophrenia Trial in Oklahoma City, Philadelphia (SPD489)

Terminated
Has Results
  • Schizophrenia
  • Oklahoma City, Oklahoma
  • +1 more
May 29, 2021

ADHD Trial in Worldwide (Lisdexamfetamine Dimesylate (LDX), Methylphenidate Hydrochloride, Placebo)

Completed
Has Results
  • ADHD
  • Lisdexamfetamine Dimesylate (LDX)
  • +2 more
  • Hoboken, Antwerp, Belgium
  • +48 more
Jun 9, 2021

ADHD Trial in United States (SPD489, Placebo)

Withdrawn
  • ADHD
  • Little Rock, Arkansas
  • +5 more
Jun 1, 2021

ADHD Trial in United States (Lisdexamfetamine Dimesylate (LDX))

Completed
Has Results
  • ADHD
  • Lisdexamfetamine Dimesylate (LDX)
  • Little Rock, Arkansas
  • +44 more
Jun 8, 2021

MDD Trial in United States (Antidepressant + SPD489 (lisdexamfetamine dimesylate), Antidepressant + )

Completed
Has Results
  • Major Depressive Disorder
  • Antidepressant + SPD489 (lisdexamfetamine dimesylate)
  • Antidepressant + placebo
  • Newport Beach, California
  • +14 more
Jun 8, 2021